On September 22, 2015 Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) reported that it plans to host a conference call and webcast on Thursday, September 24, 2015, to provide an update on the safety and tolerability profile of RAD1901, a selective estrogen receptor degrader, from the completed Phase I study of RAD1901 in 52 healthy volunteers (Press release, Radius, SEP 22, 2015, View Source [SID:1234507517]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 5-9, 2015, Radius plans to present one poster with an oral presentation from its investigational drug RAD1901 clinical development program at the AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) Meeting in Boston, MA. The title of the poster and oral presentation is:

— RAD1901, an orally available selective estrogen receptor down regulator, has potent anti-tumor activity in in vitro and in vivo models of ER+ breast cancer

On December 8-12, 2015, Radius also plans to present three posters from its investigational drug RAD1901 clinical development program at the San Antonio Breast Cancer Symposium ("SABCS") in San Antonio, TX. The titles of the three poster presentations at SABCS are as follows:

— RAD1901, a Novel Oral, Selective Estrogen Receptor Degrader ("SERD") with Single Agent Efficacy in ER+ Primary Patient Derived ERS1 Mutant Xenograft Model

— A Phase 1 Dose Escalation Study of RAD1901, an Oral Selective Estrogen Receptor Degrader, in Healthy Postmenopausal Women

— A Phase 1 Study of RAD1901, a Novel, Orally Available, Selective Estrogen Receptor Degrader, for the Treatment of ER Positive Advanced Breast Cancer

On November 17, 2015, Radius will host an Investor Day in New York City. A SAVE the DATE Card with further details will be sent out soon.